Company intelligence / Profile preview
Ensysce Biosciences
San Diego, California, United States of America
- Ownership
- Public · ENSC
- Employees
- ~7
- Development stage
- Phase 3
01
Overview
Positive results from clinical study PF614-102 showing bioequivalence between PF614 (TAAP prodrug of oxycodone) and OxyContin. Phase 3 trial for PF614 expected to begin enrollment in Q2 2025. Positive interim data reported for PF614-MPAR. PF9001 for OUD advancing toward IND-enabling studies.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small moleculesProdrugs
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
Request access →03
Partnerships
National Institute on Drug Abuse (NIDA)HEAL program
04
Financials
- Market cap
- $7.3M
- Total revenue
- $1.2M
- Enterprise value
- $6.8M
Beyond the preview
Go deeper on Ensysce Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ensysce Biosciences.